Skip to main content

Table 2 Analysis of outcomes

From: Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

  Treatment as usual Medication review tool Coefficient or OR (95 % CI)
  Baseline Follow-up Baseline Follow-up  
Outcome      
Decision Self Efficacy Scale (mean, SD) 29 (9) 32 (10) 29 (10) 30 (9) -4.16 (-9.81, 1.49)
Drug Attitude Inventory (mean, SD) 5 (4) 3 (4) 5 (4) 5 (3) 1.65 (-0.09, 3.40)
LUNSERS (mean, SD) 38 (23) 28 (19) 38 (23) 30 (20) -0.42 (-8.12, 7.29)
Brief PANSS (mean, SD) 18 (7) 16 (7) 17 (7) 16 (6) 0.13 (-2.21, 2.48)
Client Satisfaction Questionnaire (mean, SD)   28 (5)   27 (5) -0.29 (-3.04, 2.45)a
Medication Adherence Questionnaire (median, IQR) 0 (0, 1) 1 (0, 1) 0 (0, 0) 0 (0, 1) -0.44 (-0.76, -0.11)
2 or more antipsychotics taken (n/N, %) 7/29 (24) 7/24 (29) 4/31 (13) 7/26 (27) 0.89 (0.26, 3.08)b
Dose (chlorpromazine equivalents) (median, IQR) 400 (200, 600) 350 (200, 648) 250 (132, 400) 292 (200, 462) -26.02 (-97.23, 45.20)
Change in chlorpromazine equivalent baseline-FU (median, IQR)   0 (0, 50)   0 (-64, 65) 3.33 (-78.12, 84.79)
  1. Abbreviations: SD standard deviation, LUNSERS Liverpool University neuroleptic side effect rating scale, PANSS positive and negative syndrome scale, IQR interquartile range, FU follow-up, OR odds ratio
  2. aThere is no baseline adjustment for this analysis
  3. bOdds ratio. Data were too sparse to do the adjusted analysis